Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

20151,242 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet

Volume 387, Issue 10022, pp. 968-977

Field-Weighted Citation Impact: 77.48